Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 5:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 589 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: "T2DM" Condition: Type 2 Diabetes Clear all
Completed Phase 1 Interventional Results available

A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes

NCT01408888
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2189265, Sitagliptin
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Daytona Beach, Florida • Honolulu, Hawaii • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2014 · Synced Sep 23, 2026, 5:09 AM EDT
Completed Phase 3 Interventional Results available

Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.

NCT00570739
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Hypercholesterolemia, Pre-diabetes
Interventions
Metformin HCl and Colesevelam Placebo, Metformin HCl tablets and Colesevelam tablets, Colesevelam placebo, Colesevelam
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 79 Years
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
17
States / cities
Birmingham, Alabama • Los Gatos, California • Tarzana, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2010 · Synced Sep 23, 2026, 5:09 AM EDT
Active, not recruiting Not applicable Interventional

Resilience-Based Diabetes Self-Management Education (RB-DSME) for African Americans

NCT04282395
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Resilience-Based Diabetes Self-Management Education, Standard Diabetes Self-Management Education
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 23, 2026, 5:09 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus

NCT03467932
View directory record Official record
Conditions
T2DM (Type 2 Diabetes Mellitus)
Interventions
Cohort A: ORMD-0801, Placebo oral capsule, Cohort B: ORMD-0801
Drug
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Flint, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 23, 2026, 5:09 AM EDT
Completed Phase 3 Interventional

Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study)

NCT00770081
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Renal Insufficiency
Interventions
vildagliptin, sitagliptin
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 85 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
87
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Sep 23, 2026, 5:09 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects

NCT02981966
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2024 · Synced Sep 23, 2026, 5:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus

NCT06132126
View directory record Official record
Conditions
Healthy, Type 2 Diabetes Mellitus
Interventions
LY3938577, Placebo, Insulin degludec
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Anaheim, California • Miami, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Sep 23, 2026, 5:09 AM EDT
Recruiting Early Phase 1 Interventional

Acute and Chronic Effects of Oral Ketones in Subjects With HFrEF and Diabetes

NCT06108076
View directory record Official record
Conditions
Type 2 Diabetes, Heart Failure, Reduced Ejection Fraction
Interventions
Ketone Monoester (KE)
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 23, 2026, 5:09 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Fatty Acid Radiotracer Comparison Study in Heart Failure Patients

NCT01648296
View directory record Official record
Conditions
Heart Failure, Obesity, Type 2 Diabetes Mellitus, Health Normal Volunteer Subjects
Interventions
[18F]FluorbetaOx
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 23, 2020 · Synced Sep 23, 2026, 5:09 AM EDT
Completed Phase 3 Interventional Results available

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone

NCT03954834
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
28
States / cities
Huntington Park, California • Los Angeles, California • Montclair, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Sep 23, 2026, 5:09 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Preventing Type 2 Diabetes in Black Emergent Adult

NCT06848244
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Binge-Eating Disorder, Binge Eating, Obesity
Interventions
Appetite Awareness Training (AAT), Diabetes Prevention Program (DPP)
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 25 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 23, 2026, 5:09 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

NCT02769481
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Bexagliflozin, Placebo for Bexagliflozin, Glimepiride, Placebo for Glimepiride
Drug
Lead sponsor
Theracos
Industry
Eligibility
18 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
11
States / cities
Birmingham, Alabama • Huntington Park, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Sep 23, 2026, 5:09 AM EDT
Terminated Not applicable Interventional

CSII Pilot in Adolescents With Type 2 Diabetes

NCT02748122
View directory record Official record
Conditions
Diabetes
Interventions
MMT 723
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
12 Years to 23 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Sep 23, 2026, 5:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation

NCT02672839
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
LGD-6972 Solution, LGD-6972 Capsules
Drug
Lead sponsor
Ligand Pharmaceuticals
Industry
Eligibility
21 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Sep 23, 2026, 5:09 AM EDT
Completed Phase 3 Interventional Results available

A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes

NCT03882970
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Tirzepatide, Insulin Degludec
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
33
States / cities
Little Rock, Arkansas • Fresno, California • Huntington Park, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Sep 23, 2026, 5:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Investigating the Effect of Onyx Sorghum on Blood Glucose in Individuals With Type 2 Diabetes

NCT03714451
View directory record Official record
Conditions
Diabetes Type 2
Interventions
onyx sorghum, whole wheat flour
Dietary Supplement
Lead sponsor
Yale University
Other
Eligibility
30 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
3
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Sep 23, 2026, 5:09 AM EDT
Active, not recruiting Not applicable Interventional

Time-Restricted Eating for Type II Diabetes: TRE-T2D

NCT05365529
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Time Restricted Feeding, Diabetes type2
Interventions
Time-Restricted Eating, Standard of Care
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 23, 2026, 5:09 AM EDT
Completed Not applicable Interventional Results available

A 12 Month Site Randomized Trial in Adults With Type 2 Diabetes Mellitus and History of Cardiovascular Disease

NCT03936660
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Cardiovascular Diseases
Interventions
Intense Education Intervention
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
1,049 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
44
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 41 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Sep 23, 2026, 5:09 AM EDT
Completed Phase 4 Interventional Results available

Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus

NCT05114590
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin glargine/Lixisenatide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
18
States / cities
Canyon Country, California • Huntington Park, California • Lomita, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 23, 2026, 5:09 AM EDT
Active, not recruiting Not applicable Interventional

Diabetes Management Using Continuous Glucose Monitors and Remote Patient Monitoring in Underserved Populations

NCT06939413
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
Continuous glucose monitor (CGM)
Device
Lead sponsor
Diabetes Solutions International
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Greenfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 23, 2026, 5:09 AM EDT
Completed Not applicable Interventional

The Effect of Non-Surgical Periodontal Therapy on Glycemic Control and Bacterial Levels in a Mexican-American Population With Type 2 Diabetes

NCT01128374
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Periodontal Disease
Interventions
Periodontal Scaling and root planing
Procedure
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2013 · Synced Sep 23, 2026, 5:09 AM EDT
Active, not recruiting Phase 4 Interventional

Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists

NCT07325435
View directory record Official record
Conditions
Type 2 Diabetes (T2DM)
Interventions
SGLT-2 inhibitor, GLP1-RA
Drug
Lead sponsor
MaryAnn Banerji
Other
Eligibility
24 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 23, 2026, 5:09 AM EDT
Completed Phase 4 Interventional Results available

Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy

NCT03620890
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Neutral Protamine Hagedorn (NPH), Detemir insulin
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Female only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2021 · Synced Sep 23, 2026, 5:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Home Food Delivery for Diabetes Management in Patients of Rural Clinics

NCT04876053
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diet, Healthy
Interventions
Healthy Food Delivery Intervention, CDCES Consultation Only
Behavioral
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
13
States / cities
Batesville, Arkansas • Corning, Arkansas • Eureka Springs, Arkansas + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 23, 2026, 5:09 AM EDT